Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. [electronic resource]
Producer: 20121214Description: R202 p. digitalISSN:- 1478-6362
- Adolescent
- Adult
- Aged
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- C-Reactive Protein -- metabolism
- Child
- Child, Preschool
- Cryopyrin-Associated Periodic Syndromes -- blood
- Double-Blind Method
- Drug Administration Schedule
- Female
- Health Status
- Humans
- Interleukin-1beta -- antagonists & inhibitors
- Interleukin-6 -- blood
- Male
- Middle Aged
- Quality of Life
- Remission Induction
- Serum Amyloid A Protein -- metabolism
- Surveys and Questionnaires
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.